Study in Patients With Advanced Cancers Associated With Expression of DLL3

Clinical Trials, Metastatic Castration Resistant Prostate Cancer (MCRPC)

— PHENTrials.com Increasing Participation in Prostate Cancer Clinical Trials to Save Lives

NCT Number: NCT04471727
Phase: Phase 1|Phase 2
Trial Summary: A Phase 1/2 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN328 Monotherapy and HPN328 With Atezolizumab i – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Acronym:

Pin It on Pinterest